Houston, USA | May 1, 2026
Diakonos Oncology has reported positive Phase 1 clinical data for its investigational DOC1021 dendritic cell immunotherapy, demonstrating encouraging survival outcomes and immune activation in pancreatic cancer and glioblastoma patients, presented at the AACR and AAN 2026 scientific meetings. The findings highlight the therapy’s potential as a first-in-class, patient-derived immunotherapy capable of delivering durable responses in aggressive cancers with significant unmet medical need.
Phase 1 Data Shows Strong Survival and Safety Signals
The ongoing Phase 1 study in pancreatic ductal adenocarcinoma (PDAC) revealed that 5 out of 7 patients remain alive, with survival ranging from approximately 20 to 56 months, significantly exceeding typical outcomes in this challenging cancer type.
Importantly, no dose-limiting toxicities were observed, and the therapy demonstrated a favorable safety profile with mostly mild flu-like adverse events, including fatigue and fever. These results suggest that DOC1021 may offer a safe and effective treatment option in a disease where current therapies provide limited benefit. The study continues to enroll additional cohorts, including higher-dose evaluations to further assess efficacy and safety.
Immunotherapy Activates Targeted Anti-Tumor Response
Advertisement
DOC1021 is a first-in-class, patient-derived dendritic cell therapy designed to stimulate the immune system by combining tumor lysate and tumor-derived mRNA, creating a broad and targeted anti-cancer immune response.
Immune analyses demonstrated increased cytotoxic activity, including elevated granzyme B in CD8+ T cells and enhanced memory T-cell responses, indicating sustained immune engagement. This innovative approach mimics natural viral immune activation, enabling a comprehensive attack on tumor antigens without requiring genetic modification or intensive preconditioning therapies. Such advancements represent a significant step forward in personalized cancer immunotherapy.
Expanded Access Data Shows Promising Glioblastoma Outcomes
In addition to pancreatic cancer, DOC1021 was evaluated in an expanded access program for glioblastoma (GBM), where patients received the therapy alongside standard chemoradiation.All treated patients exceeded 12-month overall survival, outperforming historical benchmarks of approximately 60%, demonstrating meaningful clinical benefit in this highly aggressive brain cancer. For recurrent GBM patients, post-operative survival ranged up to 22 months, further supporting the therapy’s potential. These findings reinforce the versatility of DOC1021 across multiple tumor types and its ability to improve outcomes in difficult-to-treat cancers.
Advancing Toward Phase 2 and Regulatory Milestones
Building on these promising results, Diakonos Oncology is advancing DOC1021 into randomized Phase 2 clinical trials, particularly in glioblastoma, to further validate its efficacy.The therapy has also received FDA Fast Track and Orphan Drug Designations, reflecting its potential to address significant unmet medical needs. These designations support accelerated development and regulatory review, enabling faster access for patients if clinical benefits are confirmed. The ongoing clinical program positions DOC1021 as a leading candidate in next-generation immuno-oncology therapies.
Transforming Cancer Treatment Through Personalized Immunotherapy
The development of DOC1021 highlights the growing importance of personalized, cell-based immunotherapies in oncology, where treatments are tailored to individual patient tumor profiles. By leveraging the body’s immune system to target cancer more effectively, this approach offers the potential for durable responses and improved survival outcomes, particularly in cancers resistant to conventional therapies. As clinical evidence continues to evolve, innovative therapies like DOC1021 are expected to play a central role in transforming the future of cancer treatment and advancing precision medicine.
Source: Diakonos Oncology press release
